Key result
In patients with abdominal aortic aneurysm, the two-year survival rate was 77.7%, and all-cause mortality significantly increased over the three-decade study period (p<0.001).
Why the study?
Patients with abdominal aortic aneurysm have higher mortality due to increased cardiovascular risk, but historical trends in their cardiovascular comorbidities and medication prescriptions require characterization.
Cohort (n=7,957)
No
In patients with AAA, cardiovascular comorbidities and age at diagnosis have increased over time, while low prescription rates of cardiovascular medications highlight a need for stricter risk management to improve survival.
Increasing AAA mortality over decades may reflect rising comorbidities; hypothesis-generating for optimized medical therapy in prospective studies.
OBJECTIVE: Patients with abdominal aortic aneurysm (AAA) have higher mortality rates due to increased cardiovascular risk. This retrospective study provides an overview of cardiovascular comorbidities and medication prescriptions in patients with AAA over different time periods. METHODS: This single centre, retrospective cohort study included all AAA patients at the Amsterdam University Medical Centres from January 1989 to July 2023. Trends in cardiovascular comorbidities and medication prescriptions at AAA diagnosis were assessed across six periods: 1989 - 1998, 1999 - 2003, 2004 - 2008, 2009 - 2013, 2014 - 2018, and 2019 - 2023. Two year survival rates were analysed, and a multivariable Cox proportional hazards model was used to examine the association between cardiovascular comorbidities and medication prescriptions with all-cause mortality. RESULTS: The study included 7 957 patients (78.8% male; mean age 71.8 ± 9.9 years). Common cardiovascular comorbidities at AAA diagnosis were hypertension (39.7%), transient ischaemic attack (27.1%), and myocardial infarction (17.5%). Frequently prescribed medications included platelet inhibitors (40.5%), beta blockers (28.9%), and statins (27.4%). Over time, cardiovascular comorbidities, medication prescriptions, and age at diagnosis increased. The two year survival rate was 77.7% (95% confidence interval 76.6 - 78.7%), with a significant increase in all-cause mortality over time (log rank p < .001). Advanced age (p < .001; hazard ratio [HR] 1.065), chronic renal failure (p < .001; HR 1.545), heart failure (p = .002; HR 1.198), and chronic obstructive pulmonary disease (p < .001; HR 1.354) were associated with increased mortality risk, whereas dyslipidaemia (p < .001; HR 0.818) was associated with a decreased risk. Insulin (p < .001; HR 1.373) and diuretic use (p < .001; HR 1.223) were associated with increased mortality risk, whereas platelet inhibitors (p = .006; HR 0.899) and nitrates (p = .031; HR 0.858) were linked to a decreased risk. CONCLUSION: Cardiovascular comorbidities, medication prescriptions and age of AAA diagnosis have increased over time in patients with AAA. Low cardiovascular medication prescription rates at diagnosis suggest inadequate risk management, emphasising the need for stricter cardiovascular risk management to reduce the mortality rate.
No takes yet. Share an insight, caveat, or question.
Knippenberg et al. (2025) conducted a cohort in abdominal aortic aneurysm (n=7,957). Cardiovascular comorbidities and medication prescriptions over time was evaluated on all-cause mortality (p=<0.001). In patients with abdominal aortic aneurysm, the two-year survival rate was 77.7%, and all-cause mortality significantly increased over the three-decade study period (p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: